The Department of Education (DepEd) remains steadfast in promoting transparency, integrity, and accountability by making basic education data accessible to the public which empowers internal and ...

The Nike Mind shoes have foam nodes on the bottom of the shoe to help activate key pressure points in the brain. Nike Mind pregame mules are $95 while shoes are $145. Whether you're training or in ...

Nike’s new Mind Technology might have been launched in a pre-game slide, but now the everyday sneaker seekers can sport the invention, too. Connect with your surroundings everywhere you go. Stay ...

Strip the types and hotwire the HTML—and triple check your package security while you are at it. JavaScript in 2026 is just getting started. I am loath to inform you that the first month of 2026 has ...

With the Nike Mind 001 and 002, Nike is now in the neuroscience game. Its first foray into “mind altering” footwear comes by way of a pair of mules (the Mind 001) and a matching sneaker (the Mind 002) ...

VectorY Therapeutics Receives FDA Fast Track Designation for VTx-002, a First-in-Class Vectorized Antibody Targeting Underlying Disease Biology in ALS ~ Designation enables an enhanced development ...

In a phase 2 trial, intravesical TARA-002 showed a 72% complete response rate at any time among patients with high-grade NMIBC naïve to BCG. The investigational intravesical cell therapy TARA-002 ...

Name: Nike Mind 001 “Light Bone” Colorway: Light Bone/Hyper Crimson/Buff/Chrome SKU: HQ4307-002 MSRP: $130 USD Release Date: January 8, 2026 Where to Buy: Nike Nike is debuting a new paradigm in ...

TARA-002 demonstrates high complete response rates in BCG-naïve NMIBC patients, with 72% achieving CR and 50% maintaining it at 12 months. The treatment involves six weekly bladder instillations, ...

Laboratoires Théa has penned a deal potentially worth up to $280 million to get its hands on Iolyx Therapeutics’ phase 3-ready eye disease drug. The asset in question is ILYX-002, a topical ...

AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) ...